Glycine Treatment of Prodromal Symptoms

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00268749
Recruitment Status : Completed
First Posted : December 22, 2005
Last Update Posted : March 29, 2012
Stanley Medical Research Institute
Information provided by (Responsible Party):
Yale University

Brief Summary:
This is an open label trial of the NMDA agonist glycine used alone for symptoms that appear to be prodromal for schizophrenia in adolescents and young adults.

Condition or disease Intervention/treatment Phase
Schizophrenia Drug: glycine Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Glycine Treatment of Prodromal Symptoms
Study Start Date : July 2002
Actual Primary Completion Date : November 2004
Actual Study Completion Date : November 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia
Drug Information available for: Glycine
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1 Drug: glycine
0.8 g/kg/day

Primary Outcome Measures :
  1. Scale Of Prodromal Symptoms total score [ Time Frame: 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   14 Years to 35 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age 14-35
  • meets SIPS criteria for psychosis prodrome

Exclusion Criteria:

  • current antipsychotic medication
  • more than 4 weeks of antipsychotic medication lifetime

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00268749

Sponsors and Collaborators
Yale University
Stanley Medical Research Institute
Principal Investigator: Scott W Woods, MD Yale University

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Yale University Identifier: NCT00268749     History of Changes
Other Study ID Numbers: 02T-175
First Posted: December 22, 2005    Key Record Dates
Last Update Posted: March 29, 2012
Last Verified: March 2012

Additional relevant MeSH terms:
Prodromal Symptoms
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Signs and Symptoms
Glycine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs